The employment of targeted therapies may be useful in cholangiocarcinoma treatment and the analysis of EGFR/HER2 pathways in patients could orientate clinicians to the identification of appropriate therapeutic approach. The gene discussed is EGFR; the disease is cholangiocarcinoma.